Table 4. Outcome of subgroups in a fixed effects model.

Subgroups	OS					RFS					EFS
	N. of S.	D+/−	I2 (%)	HR (95% CI)	P	N. of S.	D+/−	I2 (%)	HR (95% CI)	P	N. of S.	D+/−	I2 (%)	HR (95% CI)	P
CN-AML	7	760/2321	74.4	1.33 (1.17–1.52)	0.001	5	562/1582	67.3	1.44 (1.22–1.71)	0.016	2	99/373	62.1	2.19 (1.46–3.27)	0.104
Intermediate-risk cytogenetics	3	225/697	67.2	1.45 (1.20–1.75)	0.047	2	183/721	0.0	1.52 (1.19–1.93)	0.937	0	—	—	—	—
Younger than 60 years of age	10	1054/4836	80.7	1.40 (1.25–1.58)	<0.001	4	597/1971	84.3	1.44 (1.22–1.71)	<0.001	3	173/1372	0.0	2.32 (1.78–3.02)	0.949
Unfavorable risk genotype	4	230/1073	0.0	2.30 (1.78–2.97)	0.862	3	194/986	0.0	2.38 (1.69–3.36)	0.726	2	73/241	0.0	1.74 (1.17–2.60)	0.78
Favorable risk genotype	6	388/1611	0.0	1.40 (0.98–1.99)	0.798	4	290/1305	41.1	1.19 (0.75–1.88)	0.165	2	73/241	0.0	1.99 (1.09–3.61)	0.432
Older than 60 years of age	2	204/492	0.0	1.71 (1.27–2.31)	0.759	0	—	—	—	—	0	—	—	—	—
R882-DNMT3A-mt/DNMT3A-wt	4	539/2144	74.5	1.30 (1.14–1.50)	0.008	3	432/1541	0.0	1.36 (1.16–1.61)	0.757	0	—	—	—	—
Non-R882-DNMT3A-mt/DNMT3A-wt	3	332/1825	89	1.08 (0.90–1.31)	<0.001	0	—	—	—	—	0	—	—	—	—

N.of S., number of studies;

D+/−, indicates ratio of number of patients with mutant DNMT3A to patients with wild-type DNMT3A;

—, reflects there is no corresponding data presented; Abbreviations: mt, mutation; wt, wild type.